Friday, October 24, 2014 10:42 am EDT
JACKSONVILLE, Fla.--(BUSINESS WIRE)--The American Association of Clinical Endocrinologists (AACE) is calling
on Congressional officials to enact crucial measures that will help
ensure the safety of the nation’s patients with diabetes.
Specifically, AACE is pushing for greater access to safe and effective
blood glucose (blood sugar) monitoring supplies and the passage of two
important bills, which are mandatory for modern-day diabetes care. See
the letter to Congress here.
The first of the bills, the Medicare CGM Access Act (H.R. 5644/S.2689),
ensures Medicare coverage of continuous glucose monitor devices (CGMs).
The CGM is an FDA-approved, physician-prescribed device that
continuously detects and displays a patient’s glucose levels, reveals
patterns in the levels that often are not detected using finger-stick
glucose measurements alone, and sounds alarms for exceedingly low or
high glucose levels. By viewing continuous data and responding to CGM
alerts, patients can respond to rising or falling blood glucose levels
before they become dangerous.
Medicare does not currently cover CGM, despite evidence of the
technology’s clinical benefit and cost benefit of the reduction in
hospitalizations due to severe hypoglycemic (low blood sugar) events,
and widespread coverage by private health plans.
AACE also is advocating for passage of its National Diabetes Clinical
Care Commission Act (H.R.
1074/S. 539). The legislation calls for the creation of a
public/private commission comprised of diabetes medical experts, patient
advocates and representatives of federal agencies involved in diabetes
care to more effectively coordinate and streamline activities now being
implemented by 35 federal departments, agencies and offices.
Further, AACE called for more rigorous FDA pre- and post-market
surveillance and enforcement activities for diabetes testing supplies
that do not meet quality standards, including the embargo of
underperforming products made in other countries, as well as rigorous
examination of competitive bidding practices that often lead to inferior
diabetes testing supplies.
AACE’s Congressional outreach efforts are the latest salvo in its
efforts to enhance access to and quality of care for the estimated 29
million Americans with diabetes.
In 2013, AACE issued Comprehensive Diabetes Management Algorithm
Consensus Statement (https://www.aace.com/files/algorithm-07-11-2013.pdf)
to provide clinicians with a practical guide about the disease-related
risks and complications and evidence-based approaches to treatment.
And in September 2014, the organization convened a diverse group of
public and private sector representatives for the AACE/ACE Consensus
Conference on Glucose Monitoring in which evolving diabetes patient
needs and barriers to care were discussed in-depth and a comprehensive
framework developed for an action plan to address conference
About the American Association of Clinical
The American Association of Clinical Endocrinologists (AACE) represents
more than 6,500 endocrinologists in the United States and abroad. AACE
is the largest association of clinical endocrinologists in the world.
The majority of AACE members are certified in endocrinology, diabetes
and metabolism and concentrate on the treatment of patients with
endocrine and metabolic disorders including diabetes, thyroid disorders,
osteoporosis, growth hormone deficiency, cholesterol disorders,
hypertension and obesity. Visit our website at www.aace.com.
About the American College of Endocrinology
The American College of Endocrinology (ACE) is the educational and
scientific arm of the American Association of Clinical Endocrinologists
(AACE). ACE is the leader in advancing the care and prevention of
endocrine and metabolic disorders by providing professional education
and reliable public health information; recognizing excellence in
education, research and service; promoting clinical research and
defining the future of clinical endocrinology. For more information,
please visit www.aace.com/college.